We are live on ! Find out more

Axsome Therapeutics

AXSM

Market cap $7.52B

143.51 USD

+1.31

0.92%

At close Updated Oct 28, 4:00 PM EDT

Pre-market

After hours

143.41

-0.10

0.07%

1 day

0.92%

5 days

-8.08%

1 month

-25.98%

3 months

-38.72%

6 months

-22.43%

Year to date

-19.69%

1 year

7.49%

5 years

262.03%

10 years

1,988.94%

About: Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.

Employees: 925

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 31%

Neutral 45.2%

Negative 23.8%

The Motley Fool

Axsome Therapeutics vs. Moderna: Consistent Revenue Growth or Sharp Volatility

Axsome Therapeutics (AXSM -1.29%) primarily discovers, develops, and exclusively commercializes innovative medical treatments targeting numerous central nervous system disorders domestically.

Axsome Therapeutics vs. Moderna: Consistent Revenue Growth or Sharp Volatility

Zacks Investment Research

Will Axsome Therapeutics (AXSM) Report Negative Earnings Next Week? What You Should Know

Axsome (AXSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Axsome Therapeutics (AXSM) Report Negative Earnings Next Week? What You Should Know

The Motley Fool

2 Growth Stocks to Hold for the Next Decade (Hint: These Aren't AI Stocks)

Axsome Therapeutics should expand its approved lineup while not facing the threat of generic competition through 2036. Eli Lilly is a leader in its core market and could diversify its lineup over the long run.

2 Growth Stocks to Hold for the Next Decade (Hint: These Aren't AI Stocks)

Zacks Investment Research

Will Auvelity Continue to Aid Axsome's Top-Line Growth in Q3?

AXSM's Auvelity sales surged 54.2% to $333 million in the first half of 2026. New indications could further expand its growth potential.

Will Auvelity Continue to Aid Axsome's Top-Line Growth in Q3?

The Motley Fool

Where Will Axsome Therapeutics Be in 2030 as Auvelity Expands Into Alzheimer's?

Axsome sees at least $8 billion in potential peak Auvelity sales. Additional drugs and pipeline candidates could fuel long-term growth.

Where Will Axsome Therapeutics Be in 2030 as Auvelity Expands Into Alzheimer's?

Zacks Investment Research

4 CNS Drug Stocks Worth Watching This World Mental Health Day

AXSM, NBIX, ALKS and ACAD are advancing CNS treatments for mental health disorders, with growing product sales, pipeline progress and new growth opportunities.

4 CNS Drug Stocks Worth Watching This World Mental Health Day

The Motley Fool

Axsome Therapeutics vs. Moderna: Which Biotech Stock Is a Better Buy in 2026?

Axsome Therapeutics is seeing massive revenue growth as it expands its footprint in the central nervous system treatment market. Moderna is moving beyond its pandemic roots by advancing a deep pipeline of mRNA-based vaccines and oncology therapies.

Axsome Therapeutics vs. Moderna: Which Biotech Stock Is a Better Buy in 2026?

Axsome Therapeutics to Report Third Quarter 2026 Financial Results on November 2

NEW YORK, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it will report its financial results for the third quarter of 2026 on Monday, November 2, 2026, before the opening of the U.S. financial markets. Axsome management will then host a conference call at 8:00 a.m. Eastern Time to discuss these results and provide a business update.

Axsome Therapeutics to Report Third Quarter 2026 Financial Results on November 2

The Motley Fool

Axsome Therapeutics vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026?

Axsome Therapeutics is delivering explosive revenue growth as it scales its commercial portfolio for central nervous system disorders. Vertex Pharmaceuticals remains a highly profitable giant with absolute dominance in cystic fibrosis and expanding reach in gene therapy.

Axsome Therapeutics vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026?

Axsome Therapeutics Announces Results of the Shared Goals Survey of Caregivers of Patients with Alzheimer's Disease Agitation Presented at Psych Congress 2026 in Connection with World Alzheimer's Day

The Shared Goals: Navigating Alzheimer's Agitation survey finds that Alzheimer's disease agitation is often only recognized after daily life is significantly disrupted Ninety-seven percent of care partners reported that agitation negatively impacted their loved one's quality of life, and three in four wish they had recognized symptoms sooner Results from the survey were recently presented at Psych Congress 2026 in New Orleans, Louisiana Survey conducted by The Harris Poll and in collaboration with CaringKind NEW YORK, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today, in connection with World Alzheimer's Day, announced results of the Shared Goals: Navigating Alzheimer's Agitation survey that highlight the profound impact that symptoms of agitation can have on people with Alzheimer's disease and their family care partners.

Axsome Therapeutics Announces Results of the Shared Goals Survey of Caregivers of Patients with Alzheimer's Disease Agitation Presented at Psych Congress 2026 in Connection with World Alzheimer's Day

See News Rankings

Price charts implemented using Lightweight Charts™